Captive capacity remains the largest impediment to faster growth of the contract manufacturing and development industry. Based on recent capital expenditure trends, it’s clear that bio/pharma companies would rather “make than buy.”
According to the latest PharmSource Trend Report, Bio/Pharma CapEx Trends 2016, bio/pharma companies have invested over $150 billion for new plant and equipment in the past 5 years, an amount at least 10 times greater than what CMOs have invested in themselves. Global and generic bio/pharma companies, in particular, have invested heavily in new capacity, especially for biopharmaceuticals and in emerging markets.
Bio/Pharma CapEx Trends 2016 analyzes recent trends in capital spending by bio/pharma companies and assesses the implications for the CMO industry.
It tracks spending by major segments of the bio/pharma industry, with detailed information on investments by global and generic biopharma companies.
It discusses the outlook for the next five years, analyzes why major bio/pharma companies continue to favor captive capacity and describes the continuing role of CMOs in the bio/pharma supply chain.
Reasons to buy
The 16-page report provides important insight that you won’t find in any other source. This report is required reading for -
CMO executives and strategic decision-makers who seriously follow the global CMO industry, including dose and API manufacturers.
Bio/Pharma sponsors that buy contract manufacturing services and need to understand contract manufacturing industry drivers.